OTTAWA
In a major win for affordable healthcare, Health Canada has officially approved two new bone-strengthening drugs from Biocon Limited. The drugs, named Bosaya and Vevzuo, are designed to treat osteoporosis and serious bone issues caused by cancer. These approvals mean that Canadian patients will soon have more high-quality, lower-cost options for managing their bone health.
Bosaya is a version of a well-known drug called Prolia. It is specifically meant for women past menopause and men who have a high risk of bone fractures. It also helps patients whose bones have been weakened by certain cancer treatments or long-term steroid use. By increasing bone mass, the drug helps prevent painful and dangerous breaks that can occur during daily activities.
The second drug, Vevzuo, is a version of Xgeva. This medication is a lifesaver for patients dealing with advanced cancers that have spread to the bones. It helps reduce the risk of “skeletal events,” such as fractures or spinal cord pressure, in people with multiple myeloma or breast and lung cancers. It also treats rare bone tumors and dangerously high calcium levels in the blood.
Biocon’s CEO, Shreehas Tambe, said this milestone shows the company’s dedication to providing top-tier medicine globally. Health Canada gave the green light after reviewing extensive data proving these new versions work just as safely and effectively as the original brand-name drugs. This move is expected to lower costs for the Canadian healthcare system while maintaining excellent patient care.
